CN112500347B - 一种苯并氮杂七元环化合物、其制备方法及用途 - Google Patents

一种苯并氮杂七元环化合物、其制备方法及用途 Download PDF

Info

Publication number
CN112500347B
CN112500347B CN202011477928.0A CN202011477928A CN112500347B CN 112500347 B CN112500347 B CN 112500347B CN 202011477928 A CN202011477928 A CN 202011477928A CN 112500347 B CN112500347 B CN 112500347B
Authority
CN
China
Prior art keywords
reaction
drying
substrate
compound
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011477928.0A
Other languages
English (en)
Other versions
CN112500347A (zh
Inventor
李青竹
贾志强
陈林
张斌
李俊龙
李江红
张翔
漆婷
戴青松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu University
Original Assignee
Chengdu University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu University filed Critical Chengdu University
Priority to CN202011477928.0A priority Critical patent/CN112500347B/zh
Publication of CN112500347A publication Critical patent/CN112500347A/zh
Application granted granted Critical
Publication of CN112500347B publication Critical patent/CN112500347B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种苯并氮杂七元环化合物,具有如下结构通式:

Description

一种苯并氮杂七元环化合物、其制备方法及用途
技术领域
本发明属于化合物技术领域,具体为一种苯并氮杂七元环化合物、其制备方法及用途。
背景技术
苯并氮杂七元环骨架广泛存在于天然产物、合成药物中,相关研究表明含有该骨架的化合物具有多种重要的生物活性和药物活性,对此类化合物的取代基修饰、结构类似物的衍生化以及进一步生物学活性再评价成为了研究热点。
如何简便的制备收率高的苯并氮杂七元环化合物是目前的研究难点。
发明内容
为了提供一种简便制备苯并氮杂七元环化合物,同时又能够取得高收率的方法,本发明公开了一种苯并氮杂七元环化合物、其制备方法及用途,实现的目的为探索出简便的苯并氮杂七元环化合物的合成方法,反应条件易操作,收率高,采用的原材料底物易获取。
为了实现上述目的,本发明公开的技术方案为:一种苯并氮杂七元环化合物,具有如下结构通式:
Figure BDA0002836232790000011
上述化学结构式中:R1选自H、Me中任意一种原子或基团;
R2选自H、Me中任意一种原子或基团;
R3选自H、F、Cl、Br、Me中任意一种原子或基团;
R4选自H、Cl、OMe中任意一种原子或基团;
R5选自Me、Et中任意一种原子或基团;
R6选自各种单取代、多取代的苯基,芳杂基,萘基。
进一步的,所述化合物选自以下结构式之一:
Figure BDA0002836232790000021
Figure BDA0002836232790000031
本发明还提供了制备上述化合物的方法,包括以下步骤:将MBH底物(1.0eq)、取代的苯甲酰基硫盐、碳酸钾和三氟甲磺酸亚铁加入反应试管中,加入DCE作为溶剂,反应72小时,TLC监测反应完成后纯化浓缩得目标产物;制备化合物的技术路线如下所示:
Figure BDA0002836232790000041
进一步的,底物1a的制备方法如下:
(1)在100mL的反应瓶中,加入取代的2-氨基苯甲酸(10mmol),在加入溶剂THF30mL,然后在冰浴条件下,缓慢加入LiAlH4(40mmol),室温搅拌1h后,TLC监测反应完毕,缓慢加入冰水淬灭,用硅藻土过滤后,用乙酸乙酯萃取,收集有机相,干燥,旋干得到粗产物,无需进一步纯化,直接进行下一步反应;
Figure BDA0002836232790000042
(2)在100mL反应瓶中,先称量取代的邻氨基苯甲醇(8.7mmol)、NaHCO3(10.4mmol),再加入1.4-二氧六环和水20mL(v/v=1:1),最后于冰浴下缓慢滴加氯甲酸乙酯(9.6mmol),室温搅拌2h后,TLC监测反应完毕,用乙酸乙酯萃取,收集有机相,干燥,旋干得到粗产物,无需进一步纯化,直接进行下一步反应;
Figure BDA0002836232790000043
(3)在100mL反应瓶中,称量上一步产物(9.0mmol),加入DCM 30mL,再加入PCC(9.0mmol),室温搅拌12h,TLC监测反应完毕,用硅藻土过滤,收集滤液旋干,经过柱层析分离纯化得到产物;
Figure BDA0002836232790000044
(4)在25mL反应瓶中,称量上一步产物(8.0mmol),DABCO(8.0mmol),再加三乙醇胺(6.5mmol)、丙烯酸甲酯(24.0mmol),室温搅拌12h,TLC监测反应完毕,用乙酸乙酯萃取,收集有机相,干燥,旋干,经过柱层析分离纯化得到产物;
Figure BDA0002836232790000051
(5)在100mL反应瓶中加入底物(3.2mmol)、对甲苯磺酸(1.6mmol),溶解于30mL甲苯中,于100℃反应1h,TLC监测反应完毕,待反应液冷却后,加入水,用乙酸乙酯萃取,收集有机相,干燥,旋干,经过柱层析分离纯化得到产物;
Figure BDA0002836232790000052
苯甲酰基硫盐制备底物1b路线如下:
Figure BDA0002836232790000053
R为烷基、噻吩、呋喃、萘基。
本发明还发现,所述苯并氮杂七元环化合物具有抗菌的活性。
本发明所具有的有益效果是:提供了一种制备所述苯并氮杂七元环化合物的能够扩大生产、规模生产的制备方法,所采用的反应底物原材料很容易获取,制备方法反应条件容易实现,最大限度地缩短了反应时间,同时又能够得到高收率。
附图说明
图1为本发明实施例一化合物晶体结构图。
具体实施方式
下面通过具体的实施例对本发明做进一步的详细描述。本发明中用的试剂都是市售可得,没有特殊说明的,均采用的是现有技术,或者常温常压的自然条件。
实施例一:本发明提供的一种苯并氮杂七元环化合物,该化合物具有如下结构通式:
Figure BDA0002836232790000061
R1为H,R2为H,R3为H,R4为H,R5为Me,R6为苯基,将该结构定义为基本体,基本体的结构式:
Figure BDA0002836232790000062
基本体的单晶结构如图1所示,其分子结构等数据见下表:
Figure BDA0002836232790000063
制备具有所述通式化合物的方法:
将MBH底物(1.0eq)、取代的苯甲酰基硫盐、碳酸钾和三氟甲磺酸亚铁加入反应试管中,加入DCE作为溶剂,反应72小时,TLC监测反应完成后纯化浓缩得目标产物;
制备化合物的技术路线如下所示:
Figure BDA0002836232790000071
进一步的,底物1a的制备方法如下:
(1)在100mL的反应瓶中,加入取代的2-氨基苯甲酸(10mmol),在加入溶剂THF30mL,然后在冰浴条件下,缓慢加入LiAlH4(40mmol),室温搅拌1h后,TLC监测反应完毕,缓慢加入冰水淬灭,用硅藻土过滤后,用乙酸乙酯萃取,收集有机相,干燥,旋干得到粗产物,无需进一步纯化,直接进行下一步反应;
Figure BDA0002836232790000072
(2)在100mL反应瓶中,先称量取代的邻氨基苯甲醇(8.7mmol)、NaHCO3(10.4mmol),再加入1.4-二氧六环和水20mL(v/v=1:1),最后于冰浴下缓慢滴加氯甲酸乙酯(9.6mmol),室温搅拌2h后,TLC监测反应完毕,用乙酸乙酯萃取,收集有机相,干燥,旋干得到粗产物,无需进一步纯化,直接进行下一步反应;
Figure BDA0002836232790000073
(3)在100mL反应瓶中,称量上一步产物(9.0mmol),加入DCM30mL,再加入PCC(9.0mmol),室温搅拌12h,TLC监测反应完毕,用硅藻土过滤,收集滤液旋干,经过柱层析分离纯化得到产物;
Figure BDA0002836232790000074
(4)在25mL反应瓶中,称量上一步产物(8.0mmol),DABCO(8.0mmol),再加三乙醇胺(6.5mmol)、丙烯酸甲酯(24.0mmol),室温搅拌12h,TLC监测反应完毕,用乙酸乙酯萃取,收集有机相,干燥,旋干,经过柱层析分离纯化得到产物;
Figure BDA0002836232790000081
(5)在100mL反应瓶中加入底物(3.2mmol)、对甲苯磺酸(1.6mmol),溶解于30mL甲苯中,于100℃反应1h,TLC监测反应完毕,待反应液冷却后,加入水,用乙酸乙酯萃取,收集有机相,干燥,旋干,经过柱层析分离纯化得到产物;
Figure BDA0002836232790000082
苯甲酰基硫盐制备底物1b路线如下:
Figure BDA0002836232790000083
R为烷基、噻吩、呋喃、萘基。
本发明的苯并氮杂七元环化合物结构通式中R1选自H、Me中任意一种原子或基团;
R2选自H、Me中任意一种原子或基团;
R3选自H、F、Cl、Br、Me中任意一种原子或基团;
R4选自H、Cl、OMe中任意一种原子或基团;
R5选自Me、Et中任意一种原子或基团;
R6选自各种取代的苯基,芳杂环,萘环。
以下为通过本发明所述的制备方法得到各种取代情况具体的化合物示例:
化合物1:
2-苯甲酰-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
methyl 2-benzoyl-2,3-dihydro-1H-benzo[b]azepine-4-carboxylate
(合成底物用苯甲酰基取代硫盐)
Figure BDA0002836232790000091
黄色固体,产率82%。
1H NMR(600MHz,CDCl3):δ(ppm):7.93(d,J=7.2Hz,2H),7.81(s 1H),7.62(t,J=7.2Hz,1H),7.51(t,J=7.8Hz,2H),7.30(d,J=7.8Hz,1H),7.17(t,J=8.4Hz,1H),6.82–6.78(m,2H),5.72(brs,1H),4.68(d,J=9.6Hz,1H),3.78(s,3H),3.59(d,J=17.4Hz,1H),2.50(dd,J=17.4,9.0Hz,1H).
13C NMR(150MHz,CDCl3):δ(ppm):198.1,168.2,147.9,140.7,135.8,134.1,133.9,130.7,128.9,128.8,126.3,119.7,118.7,117.8,58.7,52.1,37.9..
化合物2:
2-(4-氟苯甲酰基)-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯:
(合成底物用4-氟取代苯甲酰基硫盐)
Figure BDA0002836232790000092
黄色固体产率为79%。
1H NMR(600MHz,CDCl3):δ(ppm):δ(ppm):7.99–7.96(m,2H),7.80(s,1H),7.29(d,J=7.8Hz,1H),7.20–7.15(m,3H),6.82–6.77(m,2H),5.68(brs,1H),4.63(d,J=9.6Hz,1H),3.79(s,3H),3.57(d,J=17.4Hz,1H),2.48(dd,J=12.0,9.0Hz,1H).
13C NMR(150MHz,CDCl3):δ(ppm):196.5,168.2,166.1(JC-F=257.3Hz),147.7,140.7,135.8,131.6(JC-F=8.8Hz),130.8,130.4,126.2,119.6,118.3(JC-F=131.5Hz),116.2(JC-F=23.1Hz),58.7,52.1,37.9.
化合物3:
2-(4-氯苯甲酰基)-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物用4-氯取代苯甲酰基硫盐)
Figure BDA0002836232790000101
黄色固体产率为88%。
1H NMR(600MHz,CDCl3):δ(ppm):7.88(d,J=6.0Hz,2H),7.80(s 1H),7.49(d,J=12.6Hz,2H),7.29(d,J=7.2Hz,1H),7.18(t,J=6.6Hz,1H),6.82–6.77(m,2H),5.67(brs,1H),4.62(d,J=9.0Hz,1H),3.79(s,3H),3.55(d,J=15.6Hz,1H),2.48(dd,J=16.8,9.6Hz,1H).
13C NMR(150MHz,CDCl3):δ(ppm):197.0,168.1,147.7,140.8,140.5,135.8,132.3,130.8,130.2,129.3,126.1,119.6,118.8,117.9,58.8,52.2,37.9.
化合物4:
2-(4-溴苯甲酰基)-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物用4-溴取代苯甲酰基硫盐)
Figure BDA0002836232790000102
黄色固体产率为86%。
1H NMR(600MHz,CDCl3):δ(ppm):7.81–7.79(m,3H),7.66(d,J=8.4Hz,2H),7.30(d,J=7.8Hz,1H),7.18(t,J=8.4Hz,1H),6.82–6.78(m,2H),5.67(brs,1H),4.62(d,J=9.6Hz,1H),3.79(s,3H),3.55(d,J=17.4Hz,1H),2.48(dd,J=17.4,9.6Hz,1H).
13C NMR(150MHz,CDCl3):δ(ppm):197.2,168.1,147.7,140.8,135.8,132.8,132.3,130.8,130.3,129.3,126.1,119.6,118.8,117.9,58.7,52.2,37.8.
化合物5:
2-(4-甲基苯甲酰基)-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物用4-甲基取代苯甲酰基硫盐)
Figure BDA0002836232790000111
黄色固体产率为76%。
1H NMR(600MHz,CDCl3):δ(ppm):7.83(d,J=8.4Hz,2H),7.80(s,1H),7.31–7.29(m,3H),7.17(t,J=11.4Hz,1H),6.81–6.77(m,2H),5.73(brs,1H),4.64(d,J=9.0Hz,1H),3.79(s,3H),3.59(d,J=17.4Hz,1H),2.48(dd,J=12.0,9.0Hz,1H),2.43(s,3H).
13C NMR(150MHz,CDCl3):δ(ppm):197.7,168.2,147.9,144.9,140.7,135.8,131.5,130.7,129.6,129.0,126.4,119.6,118.6,117.8,58.6,52.1,38.1,21.7.
化合物6:
2-(4-甲氧基苯甲酰基)-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物用4-甲氧基取代苯甲酰基硫盐)
Figure BDA0002836232790000112
黄色固体产率为54%。
1H NMR(600MHz,CDCl3):δ(ppm):7.92(d,J=9.0Hz,2H),7.80(s,1H),7.29(d,J=7.8Hz,1H),7.17(t,J=7.2Hz,1H),6.98(t,J=9.0Hz,2H),6.80-6.77(m,2H),5.73(brs,1H),4.61(d,J=12.6Hz,1H),3.89(s,3H),3.79(s,3H),3.60(d,J=16.8Hz,1H),2.48(dd,J=16.8,9.6Hz,1H).
13C NMR(150MHz,CDCl3):δ(ppm):196.5,168.3,164.1,148.0,140.7,135.8,131.2,130.7,126.8,126.4,119.6,118.5,117.8,114.1,58.4,55.5,52.1,38.1.
化合物7:
2-(3-氯苯甲酰基)-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物用3-氯取代苯甲酰基硫盐)
Figure BDA0002836232790000121
黄色固体产率为94%。
1H NMR(600MHz,CDCl3):δ(ppm):7.92(s,1H),7.80(s,1H),7.77(d,J=8.4Hz,1H),7.59(d,J=6.6Hz,1H),7.45(t,J=7.2Hz,1H),7.30(d,J=6.6Hz,1H),7.18(t,J=8.4Hz,1H),6.78-6.82(m,2H),5.65(brs,1H),4.63(d,J=9.0Hz,1H),3.79(s,3H),3.54(d,J=17.4Hz,1H),2.49(dd,J=11.4,9.0,1H).
13C NMR(150MHz,CDCl3):δ(ppm):197.0,168.1,147.6,140.7,135.8,135.7,135.3,133.8,130.8,130.2,128.8,126.8,126.1,119.7,118.9,117.9,58.9,52.2,37.7.
化合物8:
2-(3-溴苯甲酰基)-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物用3-溴取代苯甲酰基硫盐)
methyl
2-(3-bromobenzoyl)-2,3-dihydro-1H-benzo[b]azepine-4-carboxylate
Figure BDA0002836232790000122
黄色固体产率为88%。
1H NMR(600MHz,CDCl3):δ(ppm):8.07(s,1H),7.81–7.79(m,2H),7.74(d,J=9.0Hz,1H),7.38(t,J=8.4Hz,1H),7.28(d,J=7.8Hz,1H),7.17(t,J=8.4Hz,1H),6.80(t,J=8.4Hz,1H),6.77(d,J=7.8Hz,1H),5.64(brs,1H),4.61(d,J=8.4Hz,1H),3.79(s,3H),3.53(d,J=18.6Hz,1H),2.48(dd,J=17.4,9.0Hz,1H).
13C NMR(150MHz,CDCl3):δ(ppm):196.9,168.0,147.6,140.7,136.7,135.85,135.77,131.7,130.8,130.4,127.2,126.1,123.3,119.6,118.8,117.9,58.9,52.1,37.6.
化合物9:
2-(3-硝基苯甲酰基)-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物用3-硝基取代苯甲酰基硫盐)
Figure BDA0002836232790000131
黄色固体产率为88%。
1H NMR(600MHz,CDCl3):δ(ppm):8.77(s,1H),8.48(d,J=7.8Hz,1H),8.24(d,J=7.2Hz,1H),7.81(s,1H),7.74(t,J=7.8Hz,1H),7.31(d,J=7.2Hz,1H),7.21–7.18(m,1H),6.84–6.79(m,2H),5.63(brs,1H),4.72(d,J=9.0Hz,1H),3.78(s,3H),3.53(d,J=16.8Hz,1H),2.52(dd,J=12.0,9.0Hz,1H).
13C NMR(150MHz,CDCl3):δ(ppm):196.2,168.0,148.6,147.4,140.9,135.9,135.5,134.2,131.0,130.2,128.1,125.9,123.6,119.7,119.1,118.0,59.2,52.2,37.4.化合物10:
2-(3-甲氧基苯甲酰基)-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物用3-甲氧基取代苯甲酰基硫盐)
Figure BDA0002836232790000141
黄色固体产率为81%。
1H NMR(600MHz,CDCl3):δ(ppm):7.80(s,1H),7.47–7.46(m,2H),7.40(t,J=8.4Hz,1H),7.30(d,J=7.2Hz,1H),7.18–7.16(m,2H),6.82–6.78(m,2H),5.69(brs,1H),4.65(d,J=9.0Hz,1H),3.87(s,3H),3.78(s,3H),3.59(d,J=16.8Hz,1H),2.49(dd,J=11.4,9.6Hz,1H).
13C NMR(150MHz,CDCl3):δ(ppm):198.1,168.2,160.0,147.9,140.7,135.8,135.5,130.7,129.9,126.4,121.3,120.3,119.7,118.7,117.9,113.2,58.9,55.5,52.1,38.0.
化合物11:
2-(2-氟苯甲酰基)-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物用2-氟取代苯甲酰基硫盐)
Figure BDA0002836232790000142
黄色固体,产率为48%。
1H NMR(600MHz,CDCl3):δ(ppm):7.89(t,J=7.8Hz,1H),7.76(s,1H),7.60–7.57(m,1H),7.30–7.27(m,2H),7.18–7.15(m,2H),6.81–6.77(m,2H),5.80(brs,1H),4.62(d,J=9.0Hz,1H),3.77(s,3H),3.42(d,J=16.8Hz,1H),2.55(dd,J=17.4,7.2Hz,1H).
13C NMR(150MHz,CDCl3):δ(ppm):196.2(JC-F=4.2Hz),168.0,161.1(JC-F=254.4Hz),147.8,140.4,135.8,135.4(JC-F=8.6Hz),131.2,130.7,126.2,124.9,123.2(JC-F=13.0Hz),119.8,118.7,117.7,116.8(JC-F=23.1Hz),62.3(JC-F=8.6Hz),52.0,36.7.化合物12:
2-(2-氟苯甲酰基)-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物用2-氟取代苯甲酰基硫盐)
Figure BDA0002836232790000151
黄色固体,产率为61%。
1H NMR(600MHz,CDCl3,50℃):δ(ppm):7.75(s,1H),7.47(d,J=6.6Hz,1H),7.42(t,J=6.6Hz,1H),7.32(d,J=7.2Hz,1H),7.28–7.25(m,2H),7.18(d,J=8.4Hz,1H),6.82–6.79(m,2H),5.75(brs,1H),4.61(d,J=8.4Hz,1H),3.73(s,3H),3.31(s,1H),2.53(dd,J=19.2,12.0Hz,1H),2.49(s,3H).
13C NMR(150MHz,CDCl3,50℃):δ(ppm):201.5,168.1,148.0,140.4,138.8,135.8,135.2,132.2,131.8,130.7,128.1,126.2,125.8,120.0,118.9,117.8,60.3,52.0,36.7,20.9.
化合物13:
2-(3.4-二氯苯甲酰基)-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物3.4-二氯取代苯甲酰基硫盐)
Figure BDA0002836232790000152
黄色固体,产率为80%。
1H NMR(600MHz,CDCl3):δ(ppm):8.03(s,1H),7.80(s,1H),7.72(d,J=8.4,1H),7.59(d,J=7.8Hz,1H),7.29(d,J=7.2Hz,1H),7.18(t,J=8.4Hz,1H),6.81(t,J=7.8Hz,1H),6.78(d,J=7.8Hz,1H),5.61(brs,1H),4.59(d,J=9.6Hz,1H),3.80(s,3H),3.52(d,J=16.2Hz,1H),2.47(dd,J=11.4,9.0Hz,1H).
13C NMR(150MHz,CDCl3):δ(ppm):196.1,168.0,147.5,140.8,138.6,135.8,133.8,133.6,131.0,130.9,130.7,127.7,126.0,119.6,118.9,117.9,59.0,52.2,37.6.化合物14:
2-(2-萘苯甲酰基)-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物用2-萘取代苯甲酰基硫盐)
Figure BDA0002836232790000161
黄色固体,产率为87%。
1H NMR(600MHz,CDCl3):δ(ppm):8.45(s,1H),8.00–7.94(m,3H),7.90(d,J=8.4Hz,1H),7.85(s,1H),7.64(t,J=7.8Hz,1H),7.58(t,J=7.2Hz,1H),7.33(d,J=7.2Hz,1H),7.21–7.17(m,1H),6.84–6.80(m,2H),5.78(brs,1H),4.83(d,J=9.0Hz,1H),3.77(s,3H),3.66(d,J=17.4Hz,1H),2.55(dd,J=12.0,9.6Hz,1H)
13C NMR(150MHz,CDCl3):δ(ppm):198.1,168.2,147.9,140.7,135.8,132.4,131.4,130.8,129.7,129.0,128.8,127.8,127.1,126.5,124.1,119.8,118.7,117.9,58.9,52.1,38.1.
化合物15:
2-(呋喃-2-羰基)-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物用呋喃取代的苯甲酰基硫盐)
Figure BDA0002836232790000162
黄色固体,产率为80%。
1H NMR(600MHz,CDCl3):δ(ppm):7.78(s,1H),7.65(s,1H),7.35(s,1H),7.28(d,J=7.8Hz,1H),7.16(t,J=8.4Hz,1H),6.79(t,J=8.4Hz,1H),6.76(d,J=7.8Hz,1H),6.61–6.60(m,1H),5.58(brs,1H),4.47(d,J=10.2Hz,1H),3.81(s,3H),3.66(d,J=15.6Hz,1H),2.56(dd,J=12.0,9.0Hz,1H).
13C NMR(150MHz,CDCl3):δ(ppm):186.8,168.3,150.4,147.8,147.2,140.4,135.8,130.7,126.5,119.8,119.4,118.8,117.8,112.7,59.0,52.1,37.9.
化合物16:
2-(噻吩-2-羰基)-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物用噻吩取代的苯甲酰基硫盐)
Figure BDA0002836232790000171
黄色固体,产率为79%。
1H NMR(600MHz,CDCl3):δ(ppm):7.80(s,1H),7.76(d,J=5.4Hz,1H),7.74(d,J=4.8Hz,1H),7.29(d,J=7.2Hz,1H),7.19-7.15(m,2H),6.80(t,J=8.4Hz,1H),6.77(d,J=8.4Hz,1H),5.59(brs,1H),4.50(d,J=9.0Hz,1H),3.81(s,3H),3.72(d,J=16.8Hz,1H),2.60(dd,J=11.4,9.0Hz,1H).
13C NMR(150MHz,CDCl3):δ(ppm):190.8,168.2,147.5,140.6,135.8,134.9,133.3,130.73,128.5,126.3,119.6,118.7,117.9,59.8,52.1,38.9.
化合物17:
2-苯甲酰-7-氟-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物为5-氟取代的MBH底物)
Figure BDA0002836232790000181
黄色固体,产率为56%。
1H NMR(600MHz,CDCl3):δ(ppm):7.92(d,J=9.0Hz,2H),7.68(s,1H),7.63(t,J=6.6Hz,1H),7.51(t,J=8.4Hz,2H),7.00(dd,J=9.6,3.6Hz,1H),6.91(t,J=9.0Hz,1H),6.72(q,J=4.6Hz,1H),5.60(s,1H),4.64(d,J=12.6Hz,1H),3.78(s,3H),3.54(d,J=17.4Hz,1H),2.52(dd,J=12.0,9.6Hz,1H).
13C NMR(150MHz,CDCl3):δ(ppm):198.2,168.0,156.0(JC-F=237.1Hz),144.5,139.1,134.1,134.0,128.9,128.8,128.1,120.7(JC-F=7.2Hz),120.2(JC-F=21.7Hz),119.0(JC-F=7.2Hz),118.0(JC-F=33.1Hz),58.9,52.2,38.1.
化合物18:
2-苯甲酰-7-氯-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物为5-氯取代的MBH底物)
Figure BDA0002836232790000182
黄色固体,产率为60%。
1H NMR(600MHz,CDCl3):δ(ppm):7.92(d,J=7.8Hz,2H),7.68(s,1H),7.63(t,J=7.2Hz,1H),7.51(t,J=7.8Hz,2H),7.27(s,1H),7.10(d,J=9.0Hz,1H),6.72(d,J=8.4Hz,1H),5.74(brs,1H),4.63(d,J=9.0Hz,1H),3.78(s,3H),3.59(d,J=17.4Hz,1H),2.47(dd,J=12.0,9.0Hz,1H).
13C NMR(150MHz,CDCl3):δ(ppm):197.7,167.8,146.3,139.2,134.4,134.0,133.9,130.4,128.9,128.8,127.8,123.2,120.8,119.2,58.7,52.2,37.8.
化合物19:
2-苯甲酰-7-溴-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物为5-溴取代的MBH底物)
Figure BDA0002836232790000191
黄色固体,产率为65%。
1H NMR(600MHz,CDCl3):δ(ppm):7.92(d,J=7.2Hz,2H),7.68(s,1H),7.63(t,J=7.8Hz,1H),7.51(t,J=7.2Hz,2H),7.41(s,1H),7.22(d,J=8.4Hz,1H),6.67(d,J=7.8,1H),5.76(brs,1H),4.63(d,J=7.2Hz,1H),3.78(s,3H),3.60(d,J=17.4Hz,1H),2.46(dd,J=11.4,9.0Hz,1H).
13C NMR(150MHz,CDCl3):δ(ppm):197.7,167.8,146.7,139.1,137.4,134.1,133.9,133.1,129.0,128.9,128.86,127.8,121.3,119.6,110.1,58.7,52.23,37.8.
化合物20:
2-苯甲酰-7-甲基-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物为5-甲基取代的MBH底物)
Figure BDA0002836232790000192
黄色固体,产率为82%。
1H NMR(600MHz,CDCl3):δ(ppm):7.93(d,J=7.8Hz,2H),7.77(s,1H),7.62(t,J=7.2Hz,1H),7.51(t,J=7.8Hz,2H),7.11(s,1H),7.00(d,J=7.8Hz,1H),6.70(d,J=8.4Hz,1H),5.57(brs,1H),4.65(d,J=7.8Hz,1H),3.78(s,3H),3.55(d,J=17.4Hz,1H),2.50(dd,J=12.0,9.6Hz,1H),2.27(s,3H).
13C NMR(150MHz,CDCl3):δ(ppm):198.4,168.2,145.8,140.6,135.7,134.2,133.8,131.8,128.9,128.8,127.9,126.3,119.8,117.9,59.0,52.1,38.0,20.1.
化合物21:
2-苯甲酰-6-氯-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物为6-氯取代的MBH底物)
Figure BDA0002836232790000201
黄色固体,产率为82%。
1H NMR(600MHz,CDCl3):δ(ppm):8.40(s,1H),7.94(d,J=8.4Hz,2H),7.63(t,J=7.2Hz,1H),7.51(t,J=8.4Hz,2H),7.06(t,J=8.4Hz,1H),6.92(d,J=7.2Hz,1H),6.71(d,J=7.8Hz,1H),5.79(brs,1H),4.72(d,J=9.6Hz,1H),3.81(s,3H),3.49(d,J=17.4Hz,1H),2.53(dd,J=12.6,9.6Hz,1H).
13C NMR(150MHz,CDCl3):δ(ppm):198.0,168.1,150.2,137.8,134.9,134.0,133.9,130.5,128.93,128.86,128.5,120.4,118.0,117.2,60.1,52.3,37.4.
化合物22:
2-苯甲酰-6-甲氧基-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物为6-甲氧基取代的MBH底物)
Figure BDA0002836232790000211
黄色固体,产率为68%。
1H NMR(600MHz,CDCl3):δ(ppm):8.40(s,1H),7.93(s,1H),7.91(s,1H),7.60(t,J=7.8Hz,1H),7.49(t,J=8.4Hz,2H),7.10(t,J=8.4Hz,1H),6.40(d,J=8.4Hz,1H),6.32(d,J=7.8Hz,1H),5.70(brs,1H),4.72(d,J=8.4Hz,1H),3.88(s,3H),3.77(s,3H),3.49(d,J=16.8Hz,1H),2.53(dd,J=12.6,9.6Hz,1H)
13C NMR(150MHz,CDCl3):δ(ppm):198.4,168.7,159.9,150.0,134.1,133.9,132.6,131.2,128.9,128.8,125.8,110.8,109.9,100.4,59.8,55.9,52.0,37.9.
化合物23:
2-苯甲酰-8,9-二甲基-2,3-二氢-1H-苯并[b]氮杂-4-羧酸甲酯
(合成底物为3.4二甲基取代的MBH底物)
Figure BDA0002836232790000212
黄色固体,产率为85%。
1H NMR(600MHz,CDCl3):δ(ppm):7.94(d,J=7.2Hz,2H),7.80(s,1H),7.62(t,J=6.6Hz,1H),7.51(t,J=7.2Hz,2H),7.11(d,J=7.8Hz,1H),6.68(d,J=7.8Hz,1H),5.90(brs,1H),4.67(d,J=9.6Hz,1H),3.78(s,3H),3.55(d,J=16.2Hz,1H),2.53(dd,J=11.4,9.6Hz,1H),2.31(s,3H),2.19(s,3H)
13C NMR(150MHz,CDCl3):δ(ppm):198.9,168.4,146.5,141.1,139.2,134.1,133.9,133.3,128.9,128.8,125.0,122.1,121.0,118.0,59.0,52.0,38.4,21.1,13.0.
化合物24:
2-苯甲酰-2,3-二氢-1H-苯并[b]氮杂-4-羧酸乙酯
(合成底物为乙酯取代的MBH底物)
Figure BDA0002836232790000221
黄色固体,产率为93%。
1H NMR(600MHz,CDCl3):δ(ppm):7.93(d,J=7.2Hz,2H),7.79(s,1H),7.61(t,J=6.6Hz,1H),7.50(t,J=7.8Hz,2H),7.30(d,J=8.4Hz,1H),7.16(t,J=6.6Hz,1H),6.81–6.77(m,2H),5.71(brs,1H),4.67(d,J=9.6Hz,1H),4.23(q,J=7.8Hz,2H),3.59(d,J=16.8Hz,1H),2.48(dd,J=10.8,9.0Hz,1H),1.30(t,J=7.2Hz,3H).
13C NMR(150MHz,CDCl3):δ(ppm):198.1,167.7,147.84,140.4,135.7,134.0,133.9,130.7,128.9,128.8,126.7,119.8,118.6,117.8,60.9,58.8,37.9,14.4.
苯并氮杂七元环化合物抑菌活性测试:
1.实验目的:
采用琼脂平皿二倍稀释法,测定受试化合物(化合物11)对近2-3年成都地区医院收集的临床分离致病菌(包括耐甲氧西林金黄色葡萄球菌(MRSA)、甲氧西林敏感金黄色葡萄球菌(MSSA)、耐甲氧西林表皮葡萄球菌(MRSE)、甲氧西林敏感表皮葡萄球菌(MSSE)革兰阳性菌以及肺炎克雷伯(ESBLs+)、肺炎克雷伯(ESBLs-)、大肠埃希菌(ESBLs+)、大肠埃希菌(ESBLs-)等革兰阴性菌各4株左右,共计36株左右)的MIC值。
2.实验依据:
采取美国国家临床实验室标准化委员会(Clinicaland Laboratory StandardsInstitute CLSI)推荐的琼脂二倍稀释法,进行最低抑菌浓度(MIC)的测定。
3.实验方法:
于无菌平皿内加入1ml供试药液,再加入融化的50℃MHA培养基14ml,混匀,使其每皿内所含药物终浓度依次为128、64、32、16、8、4、2、1、0.5、μg/ml;待冷却后用多点接种仪接种细菌,接种菌量约为104CFU/ml,盖上皿盖,放在培养箱中,36±1℃,孵育20-24h。培养结束后,进行肉眼观察,平皿内未见细菌生长的最低样品浓度即为其最低抑菌浓度(MIC)。同时设立不加任何样品的空白菌对照。
4.实验结果:化合物11对的甲氧西林敏感金黄色葡萄球菌(MSSE)MIC值为2ug/ml。对其显示活性。
本发明制得的化合物能够有效抑制甲氧西林敏感表皮葡萄球菌,具有良好的抗菌活性。对于其他化合物也一样具有抗菌的作用,实验方法和最终的效果都是一样的,为了减少重复的内容,故不再逐一列举其他化合物的实验内容。
以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。

Claims (4)

1.一种苯并氮杂七元环化合物,其特征在于,所述苯并氮杂七元环化合物具有如下通式结构:
Figure FDA0003497993020000011
所述通式结构选自以下结构式之一:
Figure FDA0003497993020000012
Figure FDA0003497993020000021
2.一种制备权利要求1所述化合物的制备方法,其特征在于,包括以下步骤:将1.0eq的1a底物、2a底物、碳酸钾和三氟甲磺酸亚铁加入反应试管中,加入二氯甲烷作为溶剂,反应72小时,TLC薄层色谱监测反应完成后纯化浓缩得目标产物;
制备化合物的技术路线如下所示:
Figure FDA0003497993020000022
所述R1-R6的定义与权利要求1相同。
3.根据权利要求2所述的制备方法,其特征在于:底物1a的制备方法如下:
(1)在100mL的反应瓶中,加入取代的10mmol 2-氨基苯甲酸,再加入溶剂THF 30mL,然后在冰浴条件下,缓慢加入40mmol的LiAlH4,室温搅拌1h后,TLC薄层色谱监测反应完毕,缓慢加入冰水淬灭,用硅藻土过滤后,用乙酸乙酯萃取,收集有机相,干燥,旋干得到粗产物,无需进一步纯化,直接进行下一步反应;
Figure FDA0003497993020000031
(2)在100mL反应瓶中,先称量取代的8.7mmol邻氨基苯甲醇、10.4mmol的NaHCO3,再加入20mL的1,4-二氧六环和水,1,4-二氧六环和水的体积比为1:1,最后于冰浴下缓慢滴加9.6mmol氯甲酸乙酯,室温搅拌2h后,TLC薄层色谱监测反应完毕,用乙酸乙酯萃取,收集有机相,干燥,旋干得到粗产物,无需进一步纯化,直接进行下一步反应;
Figure FDA0003497993020000032
(3)在100mL反应瓶中,称量上一步9.0mmol产物,加入二氯甲烷30mL,再加入9.0mmol氯铬酸吡啶鎓盐,室温搅拌12h,TLC薄层色谱监测反应完毕,用硅藻土过滤,收集滤液旋干,经过柱层析分离纯化得到产物;
Figure FDA0003497993020000033
(4)在25mL反应瓶中,称量上一步8.0mmol产物,8.0mmol三乙烯二胺,再加6.5mmol三乙醇胺、24.0mmol丙烯酸甲酯,室温搅拌12h,TLC薄层色谱监测反应完毕,用乙酸乙酯萃取,收集有机相,干燥,旋干,经过柱层析分离纯化得到产物;
Figure FDA0003497993020000041
(5)在100mL反应瓶中加入3.2mmol上一步的底物、1.6mmol对甲苯磺酸,溶解于30mL甲苯中,于100℃反应1h,TLC薄层色谱监测反应完毕,待反应液冷却后,加入水,用乙酸乙酯萃取,收集有机相,干燥,旋干,经过柱层析分离纯化得到产物;
Figure FDA0003497993020000042
底物2a的合成路线如下:
Figure FDA0003497993020000043
所述R1-R6的定义与权利要求1相同。
4.权利要求1所述苯并氮杂七元环化合物的用途,其特征在于,所述化合物在制备抑制甲氧西林敏感表皮葡萄球菌菌株药物中的用途。
CN202011477928.0A 2020-12-15 2020-12-15 一种苯并氮杂七元环化合物、其制备方法及用途 Active CN112500347B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011477928.0A CN112500347B (zh) 2020-12-15 2020-12-15 一种苯并氮杂七元环化合物、其制备方法及用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011477928.0A CN112500347B (zh) 2020-12-15 2020-12-15 一种苯并氮杂七元环化合物、其制备方法及用途

Publications (2)

Publication Number Publication Date
CN112500347A CN112500347A (zh) 2021-03-16
CN112500347B true CN112500347B (zh) 2022-03-29

Family

ID=74973743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011477928.0A Active CN112500347B (zh) 2020-12-15 2020-12-15 一种苯并氮杂七元环化合物、其制备方法及用途

Country Status (1)

Country Link
CN (1) CN112500347B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113336721B (zh) * 2021-06-28 2023-03-21 成都大学 一种手性n-杂环卡宾催化剂及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107295798A (zh) * 2015-03-06 2017-10-24 豪夫迈·罗氏有限公司 苯并氮杂*二甲酰胺化合物
CN111995576A (zh) * 2020-08-31 2020-11-27 三峡大学 多取代含氮杂环化合物的制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107295798A (zh) * 2015-03-06 2017-10-24 豪夫迈·罗氏有限公司 苯并氮杂*二甲酰胺化合物
CN111995576A (zh) * 2020-08-31 2020-11-27 三峡大学 多取代含氮杂环化合物的制备方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
2-乙氧羰基(羧基)-4-取代苯基-2,3-二氢-1H-苯并[b][1,4]二氮杂卓的合成及抑菌活性测定;王兰芝等;《有机化学》;20130711;第33卷;第2376-2383页 *
2-甲氧/乙氧羰基-4-氟苯基-1,5-苯并硫氮杂卓的合成、抑真菌活性及构效关系;范世丽等;《高等学校化学学报》;20141231;第35卷(第12期);第2574-2583页 *
4-氟苯基-2,3-二氢-1,5-苯并[b]硫氮杂卓类化合物的合成、结构和抑真菌活性;张静等;《高等学校化学学报》;20150430;第36卷(第4期);第687-697页 *
Construction of a Benzo[b]azepine Skeleton through Decarboxylative Ylide [6+1] Annulations with Modified Vinyl Benzoxazinanones;Qing-Zhu Li et al.;《Org. Lett.》;20210127;第23卷;第814-818页 *

Also Published As

Publication number Publication date
CN112500347A (zh) 2021-03-16

Similar Documents

Publication Publication Date Title
Aminkhani et al. Highly Efficient One‐Pot Three‐Component Synthesis and Antimicrobial Activity of 2‐Amino‐4H‐chromene Derivatives
CN112500347B (zh) 一种苯并氮杂七元环化合物、其制备方法及用途
Ramesh et al. Highly efficient regio and diastereoselective synthesis of functionalized bis-spirooxindoles and their antibacterial properties
Rao et al. Silver triflate catalyzed synthesis of 3-aminoalkylated indoles and evaluation of their antibacterial activities
CN106699766B (zh) 一种具有抗菌活性的螺靛红硫脲衍生物及其合成方法和应用
CN102140087B (zh) 一种色酮类化合物的合成方法
CN110845466B (zh) 氧杂环壬二烯衍生物、其药物组合物、其制备方法及用途
Kar et al. Synthesis of some thieno gamma lactam monocarboxylic acids with high antibacterial activity: a new look at an old molecular system
CN103910737A (zh) 手性的1,4-二氢吡喃(2,3-c)吡唑衍生物及其合成方法和应用
CN105541853B (zh) 多取代基类型的γ‑吡喃并吡咯烷酮化合物及制备方法和用途
CN112480031B (zh) 含1,3,4-噻二唑的大黄素酰胺类衍生物及合成方法与用途
CN114507158A (zh) 一类具有抗耐药菌活性的截短侧耳素α-氰基肉桂酸酯类化合物及其制备方法与应用
CN114478467B (zh) 一种氟代环己酮螺1,3-二氧六环手性衍生物及其制备方法
Liu et al. Synthesis and antibacterial evaluation of novel 4-alkyl substituted phenyl β-aldehyde ketone derivatives
CN103724357A (zh) 一种3,4-二氢吡喃并[3,2-b]吲哚-2-酮类化合物的合成方法
CN113072481A (zh) 一种吲哚并环丁烷骨架类化合物、合成方法及应用
CN101486696B (zh) 2,5-二甲基呋喃-3,4-二甲酸的制备方法
CN104910090B (zh) 二氢异噁唑类化合物及其合成方法
CN108912070A (zh) 环氧类化合物的合成方法及其农用生物活性
CN116514809A (zh) 一种苯并氮杂䓬桥环衍生物及其制备方法
CN103319430A (zh) 蒎烷基异噁唑啉类化合物及其合成方法和应用
CN114573502B (zh) 一类截短侧耳素芳杂环丙烯酸酯类化合物及其合成方法和应用
CN115974893A (zh) 一种由钯催化构建的[5+4]吲哚并氮杂九元环手性衍生物
CN104974152A (zh) 一种取代四氢喹啉衍生物及其水解产物与其合成方法和应用
CN114957113B (zh) 2-氯喹啉-3-甲醛肟-o-(n-对氟苯基)氨基甲酸酯及其制备方法与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant